Genomic uracil, its role in oncogenesis, and its possible use as a predictive cancer biomarker
- Prosjektnummer
- 46056921
- Ansvarlig person
- Antonio Sarnio
- Institusjon
- NTNU, IKOM
- Prosjektkategori
- Postdoc-stipend 2015
- Helsekategori
- Cancer
- Forskningsaktivitet
- 1. Underpinning, 4. Detection and Diagnosis
This work will lead to the establishment of prognostic tools in cancer
Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation.
Science 2018 11 16;362(6416):834-839.
PMID: 30442810
MutT homologue 1 (MTH1) catalyzes the hydrolysis of mutagenic O6-methyl-dGTP.
Nucleic Acids Res 2018 Nov 16;46(20):10888-10904.
PMID: 30304478
dUTPase inhibition augments replication defects of 5-Fluorouracil.
Oncotarget 2017 Apr 04;8(14):23713-23726.
PMID: 28423595
Uracil Accumulation and Mutagenesis Dominated by Cytosine Deamination in CpG Dinucleotides in Mice Lacking UNG and SMUG1.
Sci Rep 2017 Aug 03;7(1):7199. Epub 2017 aug 3
PMID: 28775312
Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
PLoS One 2015;10(3):e0119857. Epub 2015 mar 13
PMID: 25769101
AID expression in B-cell lymphomas causes accumulation of genomic uracil and a distinct AID mutational signature.
DNA Repair (Amst) 2015 Jan;25():60-71. Epub 2014 nov 24
PMID: 25486549
Uracil in DNA - necessary intermediate for antibody maturation and mutagenic lesion
- Disputert:
- juni 2015
- Hovedveileder:
- Hans E. Krokan, Per Arne Aas
- Nina-Beate Liabakk Prosjektdeltaker
- Mirta Mittelstedt Leal de Sousa Forsker
- Håkon Hov Forsker
- Henrik Peter Sahlin Pettersen Forsker
- Marie Benner Lundbæk Postdoktorstipendiat
- Bodil Merete Kavli Forskningsgruppeleder
- Hans Einar Krokan Hovedveileder
- Antonio Sarno Postdoktorstipendiat
- Geir Slupphaug Prosjektdeltaker
- Lars Hagen Prosjektdeltaker
- Harald Aarset Prosjektdeltaker
- Unn Merete Fagerli Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Helse Midt-Norge RHF - Samarbeidsorganet og FFU